NeRRe Therapeutics appoints Mary Kerr as chief executive

23 September 2015

UK clinical-stage neurokinin receptor specialist company NeRRe Therapeutics has appointed Mary Kerr as chief executive.

Prior to joining NeRRe, Dr Kerr held a range of senior leadership roles and joins from GlaxoSmithKline (LSE: GSK), where she was senior vice president and global franchise leader for its immuno-inflammation and infectious diseases portfolio.

Martin Edwards, chairman of NeRRe, said: “At this critical stage of the company development, Mary is a great addition to the NeRRe Therapeutics team and I am delighted to welcome her. Her broad range of business skills and experience will provide invaluable direction to the company and the future development of its rich portfolio.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology